“We are happy to have Venu join the Veeda family and we are sure that with his experience and knowledge he will help to continue Veeda grow in early clinical development and augment our position in the market as leaders in this field”, said Binoy Gardi, Group Managing Director, Veeda.

Mr. Venu Madhav is post graduate in pharmacy and having 19 years of experience in diverse areas of clinical research. He has been associated with reputed companies likes Ranbaxy and Sun Pharma especially in the growth period of these organizations. His contribution for the growth of these organizations is noticeable.

Mr. Venu carries rich experience in planning bioequivalence studies from pilot to pivotal stage for generic formulations. He has designed clinical, bioanalytical, pharmacokinetic and statistical aspects of bioavailability and bioequivalence studies. He is credited to have coordinated for more than 450 pilot and pivotal biostudies for conventional formulations and extended release formulations.

He has held the responsibility for developing complex bioanalytical methods for hormonal and peptide products apart for the effective utilization of 250 methods. He has also handled more than 150 pilot and 300 pivotal bioanalytical projects with GLP compliance. Pivotal biostudies were audited by most of the regulatory inspections and subsequent approval.

During his tenure Mr. Venu has also handled pharmacokinetic and statistical evaluation of data for ANDA/ NDA submissions. He has conducted a workshop as well on ‘Bioequivalence Studies’ for Bahrain and Oman regulatory officials.